134 related articles for article (PubMed ID: 7083459)
1. Etoposide as a single agent in relapsed advanced lymphomas. A phase II study.
Taylor RE; McElwain TJ; Barrett A; Peckham MJ
Cancer Chemother Pharmacol; 1982; 7(2-3):175-7. PubMed ID: 7083459
[TBL] [Abstract][Full Text] [Related]
2. High-dose ifosfamide in combination with etoposide and epirubicin (IVE) in the treatment of relapsed/refractory Hodgkin's disease and non-Hodgkin's lymphoma: a report on toxicity and efficacy.
Proctor SJ; Taylor PR; Angus B; Wood K; Lennard AL; Lucraft H; Carey PJ; Stark A; Iqbal A; Haynes A; Russel N; Leonard RC; Culligan D; Conn J; Jackson GH
Eur J Haematol Suppl; 2001 Jul; 64():28-32. PubMed ID: 11486397
[TBL] [Abstract][Full Text] [Related]
3. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
Hagemeister FB
Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
[TBL] [Abstract][Full Text] [Related]
4. [Phase II study of NK 171 (etoposide) on malignant lymphomas and acute leukemia. A cooperative study group on NK 171 in hematological malignancies].
Kimura K; Yamada K; Yoshida T
Gan To Kagaku Ryoho; 1986 Mar; 13(3 Pt 1):496-501. PubMed ID: 3954373
[TBL] [Abstract][Full Text] [Related]
5. [Phase II study of etoposide (NK 171) in advanced hematological malignancies].
Yoshida T; Nakanishi J; Ito K; Kobayashi S; Ohtake S; Nakamura S; Hattori K
Gan To Kagaku Ryoho; 1984 Aug; 11(8):1579-84. PubMed ID: 6476835
[TBL] [Abstract][Full Text] [Related]
6. Ifosfamide and etoposide as salvage therapy for non-Hodgkin's lymphoma.
Hagberg H; Cavallin-Ståhl E; Lind J
Scand J Haematol; 1986 Jan; 36(1):61-4. PubMed ID: 3952466
[TBL] [Abstract][Full Text] [Related]
7. Etoposide and adriamycin containing combination chemotherapy (HOPE-Bleo) for relapsed Hodgkin's disease.
Perren TJ; Selby PJ; Milan S; Meldrum M; McElwain TJ
Br J Cancer; 1990 Jun; 61(6):919-23. PubMed ID: 1695523
[TBL] [Abstract][Full Text] [Related]
8. VP-16-213 in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone in the treatment of non-Hodgkin's lymphomas.
Hansen MM; Bloomfield CD; Jørgensen J; Ersbøll J; Pedersen-Bjergaard J; Blom J; Nissen NI
Cancer Treat Rep; 1980; 64(10-11):1135-7. PubMed ID: 7459900
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of VP-16-213 in malignant lymphoma and melanoma.
Cecil JW; Quagliana JM; Coltman CA; Al-Sarraf M; Thigpen T; Groppe CW
Cancer Treat Rep; 1978 May; 62(5):801-3. PubMed ID: 657164
[TBL] [Abstract][Full Text] [Related]
10. Cis-dichlorodiammineplatinum (II), VP 16-213, and prednisone (DVP regimen) in the treatment of pretreated advanced malignant lymphomas.
Fosser VP; Salvagno L; Segati R; Pappagallo GL; Ferrazzi E; Sileni VC; Fiorentino MV
Tumori; 1982 Dec; 68(6):515-8. PubMed ID: 6762740
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic trials with VP-16-213 and VM-26: active agents in small cell lung cancer, non-Hodgkin's lymphomas, and other malignancies.
Radice PA; Bunn PA; Ihde DC
Cancer Treat Rep; 1979 Aug; 63(8):1231-9. PubMed ID: 225026
[No Abstract] [Full Text] [Related]
12. [Phase II study of etoposide (VP-16) in the form of oral capsules for malignant lymphomas].
Konishi I; Kitani T; Nagai K; Kanamaru A; Kohsaki M; Masaoka T; Shibata H; Horiuchi A; Tsubaki K; Kawagoe H
Gan To Kagaku Ryoho; 1985 Jul; 12(7):1482-6. PubMed ID: 4015122
[TBL] [Abstract][Full Text] [Related]
13. The results of Vepesid therapy in the treatment of malignant lymphomas.
Pawlicki M; Sliz E; Rachtan J
Neoplasma; 1990; 37(1):85-9. PubMed ID: 2320184
[TBL] [Abstract][Full Text] [Related]
14. Etoposide as single agent and in combination with cis-platinum for malignant lymphomas.
Kroner T; Obrecht JP; Jungi WF
Cancer Treat Rev; 1982 Jun; 9 Suppl():39-43. PubMed ID: 6889920
[No Abstract] [Full Text] [Related]
15. [A phase II clinical trial of oral VP 16-213 in advanced non-Hodgkin's lymphoma].
Nakada H; Ogawa M; Ingaki J; Horikoshi N; Inoue K; Usui N; Adachi K; Tada A; Yamazaki H; Mukaiyama T
Gan To Kagaku Ryoho; 1984 Aug; 11(8):1644-8. PubMed ID: 6476837
[TBL] [Abstract][Full Text] [Related]
16. Phase I/II study of high-dose cyclophosphamide, etoposide and cisplatin followed by autologous bone marrow or peripheral blood stem cell transplantation in patients with poor prognosis Hodgkin's disease or non-Hodgkin's lymphoma.
Klumpp TR; Mangan KF; Glenn LD; Malaspina DR; Cropper T; Mullaney M; Macdonald JS
Bone Marrow Transplant; 1993 Oct; 12(4):337-45. PubMed ID: 7506091
[TBL] [Abstract][Full Text] [Related]
17. Results of a clinical phase I dose-escalation study of cytarabine in combination with fixed-dose vinorelbine, paclitaxel, etoposide and cisplatin for the treatment of relapsed/refractory lymphoma.
Lonial S; Arellano M; Hutcherson D; Langston A; Flowers C; Heffner LT; Winton E; Jo Lechowicz M; Waller EK
Leuk Lymphoma; 2006 Oct; 47(10):2155-62. PubMed ID: 17071490
[TBL] [Abstract][Full Text] [Related]
18. Phase I study of involved-field radiotherapy preceding autologous stem cell transplantation for patients with high-risk lymphoma or Hodgkin's disease.
Dawson LA; Saito NG; Ratanatharathorn V; Uberti JP; Adams PT; Ayash LJ; Reynolds CM; Silver SM; Schipper MJ; Lichter AS; Eisbruch A
Int J Radiat Oncol Biol Phys; 2004 May; 59(1):208-18. PubMed ID: 15093918
[TBL] [Abstract][Full Text] [Related]
19. Ifosfamide, etoposide, cytarabine, and dexamethasone as salvage treatment followed by high-dose cyclophosphamide, melphalan, and etoposide with autologous peripheral blood stem cell transplantation for relapsed or refractory lymphomas.
Schütt P; Passon J; Ebeling P; Welt A; Müller S; Metz K; Moritz T; Seeber S; Nowrousian MR
Eur J Haematol; 2007 Feb; 78(2):93-101. PubMed ID: 17313557
[TBL] [Abstract][Full Text] [Related]
20. The rationale of therapy with mitoxantrone in non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Co-operative Study Group, (NHLCSG) Italy.
Chisesi T
Leuk Lymphoma; 1993 Jan; 9(1-2):63-9. PubMed ID: 8477203
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
